Tri Locum Partners
Latest statistics and disclosures from Tri Locum Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are JNJ, VRTX, LLY, ASND, DXCM, and represent 52.17% of Tri Locum Partners's stock portfolio.
- Added to shares of these 10 stocks: ASND (+$69M), ELVN (+$44M), AXSM (+$39M), VRTX (+$36M), RVMD (+$28M), LLY (+$18M), CYTK (+$17M), JAZZ (+$15M), ARGX (+$9.2M), DXCM (+$8.2M).
- Started 5 new stock positions in CYTK, BBNX, ELVN, RVMD, ASND.
- Reduced shares in these 9 stocks: TMO (-$65M), Ascendis Pharma A S (-$58M), ISRG (-$42M), NUVL (-$32M), MDGL (-$19M), UTHR (-$13M), DFTX (-$9.7M), TEVA (-$9.3M), DNTH.
- Sold out of its positions in Ascendis Pharma A S, NUVL, TMO.
- Tri Locum Partners was a net buyer of stock by $48M.
- Tri Locum Partners has $813M in assets under management (AUM), dropping by 14.13%.
- Central Index Key (CIK): 0001826434
Tip: Access up to 7 years of quarterly data
Positions held by Tri Locum Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Tri Locum Partners
Tri Locum Partners holds 19 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Johnson & Johnson (JNJ) | 13.3 | $108M | +2% | 425k | 253.97 |
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 12.3 | $100M | +56% | 202k | 496.73 |
|
| Eli Lilly & Co. (LLY) | 11.3 | $92M | +23% | 77k | 1199.43 |
|
| Ascendis Pharma A/s Ord Shs (ASND) | 8.5 | $69M | NEW | 259k | 266.72 |
|
| Dex (DXCM) | 6.8 | $55M | +17% | 821k | 67.35 |
|
| Axsome Therapeutics (AXSM) | 6.6 | $54M | +253% | 219k | 244.77 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 6.6 | $53M | +39% | 222k | 240.97 |
|
| Enliven Therapeutics (ELVN) | 5.4 | $44M | NEW | 867k | 50.75 |
|
| Argenx Se Sponsored Adr (ARGX) | 4.7 | $39M | +31% | 42k | 927.77 |
|
| Madrigal Pharmaceuticals (MDGL) | 4.5 | $37M | -33% | 68k | 536.95 |
|
| Revolution Medicines (RVMD) | 3.5 | $28M | NEW | 152k | 187.28 |
|
| United Therapeutics Corporation (UTHR) | 3.1 | $26M | -33% | 47k | 541.83 |
|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 3.1 | $25M | -26% | 747k | 33.88 |
|
| Tarsus Pharmaceuticals (TARS) | 2.5 | $21M | +29% | 328k | 62.94 |
|
| Intuitive Surgical Com New (ISRG) | 2.3 | $19M | -68% | 48k | 397.68 |
|
| Cytokinetics Com New (CYTK) | 2.0 | $17M | NEW | 194k | 85.19 |
|
| Dianthus Therapeutics (DNTH) | 1.4 | $12M | -17% | 121k | 97.48 |
|
| Beta Bionics (BBNX) | 1.0 | $7.7M | NEW | 493k | 15.67 |
|
| Definium Therapeutics Com Shs (DFTX) | 0.9 | $7.7M | -55% | 163k | 47.04 |
|
Past Filings by Tri Locum Partners
SEC 13F filings are viewable for Tri Locum Partners going back to 2020
- Tri Locum Partners 2026 Q2 filed Aug. 14, 2026
- Tri Locum Partners 2026 Q1 filed May 18, 2026
- Tri Locum Partners 2025 Q4 filed Feb. 17, 2026
- Tri Locum Partners 2025 Q3 filed Nov. 14, 2025
- Tri Locum Partners 2025 Q2 filed Aug. 14, 2025
- Tri Locum Partners 2025 Q1 filed May 14, 2025
- Tri Locum Partners 2024 Q4 filed Feb. 14, 2025
- Tri Locum Partners 2024 Q3 filed Nov. 14, 2024
- Tri Locum Partners 2024 Q2 filed Aug. 14, 2024
- Tri Locum Partners 2024 Q1 filed May 15, 2024
- Tri Locum Partners 2023 Q4 filed Feb. 14, 2024
- Tri Locum Partners 2023 Q3 filed Nov. 14, 2023
- Tri Locum Partners 2023 Q2 filed Aug. 14, 2023
- Tri Locum Partners 2023 Q1 filed May 15, 2023
- Tri Locum Partners 2022 Q4 filed Feb. 14, 2023
- Tri Locum Partners 2022 Q3 filed Nov. 14, 2022